UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 30, 2013

RPX Corporation (Exact name of registrant as specified in its charter)

Delaware	001-35146	26-2990113
(State or other Jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)
	One Market Plaza	
	Suite 800	
	San Francisco, CA 94105	
(Ac	ddress of principal executive offices, including zip code)	
	(866) 779-7641	
	(Registrant's telephone number, including area code)	
· ·	ner Name or Former Address, if Changed Since Last Repo	
Check the appropriate box below if the Form 8-K filir brovisions (see General Instruction A.2):	ng is intended to simultaneously satisfy the filing obl	igation of the registrant under any of the following
Miles and a second section as a section	and the Committee Art (17 CFR 220 425)	
Written communications pursuant to Rule 425	b under the Securities Act (17 CFR 230.425)	
Soliciting material pursuant to Rule 14a-12 ur	nder the Exchange Act (17 CFR 240.14a-12)	
Due	4 to Dula 144 2/k) and an the Earth are a Act (17 CED)	240 144 275))
Pre-commencement communications pursuant	t to Rule 14d-2(b) under the Exchange Act (17 CFR	240.14d-2(b))
Pre-commencement communications pursuant	t to Rule 13e-4(c) under the Exchange Act (17 CFR 2	240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On July 30, 2013, RPX Corporation issued a press release announcing its financial results for the quarter ended June 30, 2013. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release issued by RPX Corporation dated July 30, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RPX Corporation

By: /s/ MARTIN E. ROBERTS

Martin E. Roberts General Counsel

Dated: July 30, 2013



RPX Announces Second Quarter 2013 Financial Results

SAN FRANCISCO – **July 30, 2013** – RPX Corporation (NASDAQ: RPXC), the leading provider of patent risk management solutions, today announced its financial results for the second quarter ended June 30, 2013.

Financial Highlights

- Revenue for the second quarter of fiscal 2013 totaled \$57.5 million
- Subscription revenue for the second quarter was \$55.0 million, up 20% compared to \$45.8 million in the prior year period
- GAAP net income for the second quarter of fiscal 2013 was \$10.7 million, or \$0.20 per pro forma diluted share[1]
- Non-GAAP net income for the second quarter of fiscal 2013 was \$14.0 million or \$0.26 per pro forma diluted share^[1]

"We are very pleased with our results in the second quarter," said John Amster, Chief Executive Officer of RPX Corporation. "We grew our client network to 157 members, wrote eight new insurance policies, and spent over \$39 million on patent assets to continue to clear patent risk for our clients."

Summary Results

Revenue for the second quarter increased to \$57.5 million, compared to \$55.2 million in the second quarter of 2012.

Net acquisition spend during the quarter totaled \$39.1 million, and included eight new acquisitions of patent assets, in addition to the exercise of previously negotiated options to acquire licenses for new clients.

GAAP net income for the quarter was \$10.7 million or \$0.20 per diluted share, compared to \$13.2 million or \$0.25 per diluted share in the second quarter of 2012. Net income was \$0.20 per pro forma diluted share^[1] in the second quarter, compared to \$0.25 per pro forma diluted share^[1] in the second quarter of 2012.

Non-GAAP net income for the quarter, which excludes stock-based compensation and the amortization of acquired intangibles (in each case, net of tax), was \$14.0 million or \$0.26 per pro forma diluted share^[1], compared to \$15.4 million or \$0.29 per pro forma diluted share^[1] in the second quarter of 2012.

As of June 30, 2013, RPX had cash, cash equivalents and short-term investments of \$259.3 million.

Business Outlook

This outlook reflects the Company's current and preliminary view and may be subject to change. Please see the paragraph regarding "Forward-Looking Statements" at the end of this news release.

The Company provided the following business outlook for the third quarter of fiscal 2013:

Subscription revenue ^[2]	\$57.2 - \$57.7 million
Fee-related revenue	\$0.5 million
Total revenue	\$57.7 - \$58.2 million
Net income (non-GAAP)	\$10.6 - \$11.1 million
Effective tax rate (non-GAAP)	37%
Pro forma weighted-average diluted shares outstanding	54.2 million

The Company provided the following business outlook for the full year 2013:

Subscription revenue ^[2]	\$219 - \$225 million
Fee-related revenue	\$10 - \$11 million
Total revenue	\$229 - \$235 million
Cost of revenue (non-GAAP)	\$103 - \$105 million
SG&A (non-GAAP)	\$46 - \$48 million
Net income (non-GAAP)	\$50 - \$53 million
Effective tax rate (non-GAAP)	37%
Pro forma weighted-average diluted shares outstanding	53.7 million
Net acquisition spend	\$120 - \$125 million

The above outlook is forward-looking. Actual results may differ materially. Please refer to the information under the caption "Use of Non-GAAP Financial Information" below.

Conference Call

RPX management will host a conference call and live webcast for analysts and investors at 2:00 p.m. PDT/5:00 p.m. EDT on July 30, 2013. Parties in the United States and Canada can access the call by dialing 1-877-941-9205, using conference code 4628430. International parties can access the call by dialing 1-480-629-9818, using conference code 4628430.

RPX will offer a live webcast of the conference call which can be accessed from the "Investor Relations" section of the Company's website at http://ir.rpxcorp.com. An audio replay of the conference call will also be available approximately two hours after the call and will be available for 30 days. To hear the replay, parties in the United States and Canada should call 1-800-406-7325 and enter conference code 4628430. International parties should call 1-303-590-3030 and enter conference code 4628430.

^[1] Pro forma diluted shares computed to give effect to the shares of restricted stock outstanding as of the original date of issuance.

^[2] Subscription revenue is comprised of revenue generated from membership subscription services and premiums earned from insurance policies.

About RPX Corporation

RPX Corporation (NASDAQ: RPXC) is the leading provider of patent risk solutions, offering defensive buying, acquisition syndication, patent intelligence and advisory services. Since its founding in 2008, RPX has introduced efficiency to the patent market by providing a rational alternative to litigation. The San Francisco-based company's pioneering approach combines principal capital, deep patent expertise, and client contributions to generate enhanced patent buying power. By acquiring patents, RPX helps to mitigate and manage patent risk for its growing client network.

Use of Non-GAAP Financial Information

This news release dated July 30, 2013 contains non-GAAP financial measures. Tables are provided in this news release that reconcile the non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures include non-GAAP cost of revenue, non-GAAP selling, general and administrative expenses, non-GAAP net income, and non-GAAP net income per share.

To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, management believes that these non-GAAP measures provide useful information about the Company's core operating results and thus are appropriate to enhance the overall understanding of the Company's past financial performance and its prospects for the future. Management is excluding from its non-GAAP operating results stock-based compensation expenses (inclusive of related employer payroll taxes), the amortization of acquired intangible assets and related tax effects. Management uses these non-GAAP measures to evaluate the Company's financial results, and believes investors wish to exclude the effects of such items in comparing our financial performance with that of other companies. The adjustments to the Company's GAAP results are made with the intent of providing both management and investors a more complete understanding of the Company's underlying operational results, trends and performance. The presentation of additional information is not meant to be considered in isolation or as a substitute for or superior to financial results determined in accordance with GAAP.

Forward-Looking Statements

This news release and its attachments contain forward-looking statements within the meaning of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include statements regarding RPX's future financial performance as well as any statements regarding the Company's strategic and operational plans. The Company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may contribute to such differences include, among others, the Company's ability to maintain an adequate rate of growth, the impact of the current economic climate on the Company's business, the Company's ability to effectively manage its growth and changes in its executive team, and the Company's ability to attract new clients and retain existing clients. Forward-looking statements are often identified by the use of words such as, but not limited to, "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "plan," "project," "seek," "should," "target," "will," "would," and similar expressions or variations intended to identify forward-looking statements. More information about potential factors that could affect the Company's business and financial results is contained in the Company's most recent annual report on Form 10-K, its quarterly reports on Form 10-Q, and the Company's other filings with the SEC. The Company does not intend, and undertakes no duty, to update any forward-looking statements to reflect future events or circumstances.

#

Contacts:

Investor RelationsMedia RelationsJoAnn HorneKaustuva DasMarket Street PartnersRPX Corporation+1-415-445-3233+1-415-529-3105ir@rpxcorp.commedia@rpxcorp.com

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

(
	Three Months Ended				Six Months Ended					
	June 30,				June 30,					
	 2013		2012		2013		2012			
Revenue	\$ 57,481	\$	55,238	\$	118,675	\$	99,087			
Cost of revenue	24,694		20,511		48,364		38,528			
Selling, general and administrative expenses	15,736		13,533		30,209		26,756			
(Gain) loss on sale of patent assets, net	 126		_		126		(177)			
Operating income	 16,925		21,194		39,976		33,980			
Other income, net	63		47		114		27			
Income before provision for income taxes	 16,988		21,241		40,090		34,007			
Provision for income taxes	 6,291		8,053		14,698		12,738			
Net income	\$ 10,697	\$	13,188	\$	25,392	\$	21,269			
Net income available to common stockholders:										
Basic	\$ 10,691	\$	12,976	\$	25,370	\$	20,782			
Diluted	\$ 10,691	\$	12,985	\$	25,370	\$	20,806			
Net income per common share:										
Basic	\$ 0.21	\$	0.26	\$	0.49	\$	0.43			
Diluted	\$ 0.20	\$	0.25	\$	0.48	\$	0.40			
Weighted-average shares used in computing net income per common share:										
Basic	 51,774		49,454		51,489		48,881			
Diluted	 53,463		51,787		53,055		51,517			

Condensed Consolidated Balance Sheets

(in thousands)

	June 30, 2013	December 31, 2012
Assets		
Current assets:		
Cash and cash equivalents	\$ 99,278	\$ 73,638
Short-term investments	160,027	126,092
Accounts receivable	24,928	25,144
Other receivables		33,775
Prepaid expenses and other current assets	5,859	5,237
Deferred tax assets	7,954	7,658
Total current assets	298,046	271,544
Patent assets, net	221,362	199,314
Property and equipment, net	3,639	3,144
Intangible assets, net	2,458	3,226
Goodwill	16,460	16,460
Other assets	838	279
Total assets	\$ 542,803	\$ 493,967
Liabilities and stockholders' equity		
Current liabilities:		
Accounts payable	\$ 698	\$ 568
Accrued liabilities	5,118	7,206
Deferred revenue	111,744	101,249
Deferred payment obligations	500	500
Other current liabilities	1,565	1,813
Total current liabilities	119,625	111,336
Deferred revenue, less current portion	5,829	3,122
Deferred tax liabilities	17,430	18,108
Other liabilities	2,185	1,142
Total liabilities	145,069	133,708
Stockholders' equity:		
Common stock	5	5
Additional paid-in capital	293,555	281,530
Retained earnings	104,136	78,744
Accumulated other comprehensive income (loss)	38	(20)
Total stockholders' equity	397,734	360,259
Total liabilities and stockholders' equity	\$ 542,803	\$ 493,967

Condensed Consolidated Statements of Cash Flows

(in thousands)

Cash Huse from operating activities 7.5.2		Six Mor	nths Ended June 30,
Nememe \$ 25,392 \$ 21,000 Adjustments to reconcile ent income to net cash provided by operating activities: Secretary in the provided by operating activities: Depreciation and amoritzation 47,798 38,988 Stock-based compensation 2,000 5,012 Excess tax benefit from stock-based compensation 2,000 6,02 Imputed interest on deferred payment obligations 2 9.3 (Gair) loss on sale of patent assets 12 (1,77 Amoritzation of premium on investments 2,995 2,403 Other datases 13 (1,100 5,808 Other rectivable 21 2,61 2,61 Other rectivable 33,75 - - Peppald expenses and other assets 3,375 - - Accounts payable 1,100 3,095 - Account and other liabilities 1,100 3,095 - Peppald expenses and other assets 4,100 3,095 - - Accounts payable 4,100 3,095 - - - -		2013	2012
Adjustments to reconcile net income to net cash provided by operating activities: 47,798 38,38 Depociation and anorization 8,186 5,012 Stock-based compensation (2,009) (5,423) Imputed interest on deferred payment obligations 2,095 93 (Gain) loss on sale of patent assets 126 0,773 Amortization of premium on investments 2,995 2,473 Deferred taxes 0,100 58 Other 313 (11) Changes in assets and liabilities: 216 2,617 Accounts receivable 33,75 — Other receivables 33,75 — Other receivables 33,75 — Accruent spayable 13,0 (26,90 Accruent payable 13,20 (2,93) Deferred revenue 13,20 (2,93) Deferred revenue 13,20 (2,93) Deferred revenue 9,895 12,932 Martities of investments classified as available-for-sale (89,50) 12,932 Muchase of investments classified as availab	Cash flows from operating activities		
Depreciation and amortization 47,798 38,938 Stock-based compensation (2,009) (5,423) Exces tax benefit from stock-based compensation (2,009) (5,423) Imputed interest on deferred payment obligations — 93 (Gain) loss on sale of patent assets 126 (177) Amortization of premium on investments 2,995 2,473 Deferred taxes (1,906) 588 Other 13 (11) Changes in assets and liabilities 33,755 — Prepaid expenses and other assets 33,475 — Perpaid expenses and other assets 33,375 — Peppaid expenses and other assets 130 (226) Accounts receivable 13 (226) Accused and other liabilities 1,191 3,987 Deferred revenue 13,202 2,349 Net cash provided by operating activities 123,79 62,522 Business of investments classified as available-for-sale 68,950 107,932 Maturities of investments classified as available-for-sale 1,09	Net income	\$ 25,	392 \$ 21,269
Stock-based compensation 8,186 5,012 Excess tax benefit from stock-based compensation (2,009) (5,423) Imputed interest on deferred payment obligations 9.3 (Gain) loss on sale of patent assets 126 (177) Amortization of premium on investments 2,995 2,473 Deferred taxes (1,906) 588 Other 213 (110) Changes in assets and liabilities 216 2,617 Accounts receivable 216 2,617 Other receivables 33,755 - Prepaid expenses and other assets 3,348 3,745 Accounts payable 130 (226) Accrued and other liabilities 1,191 (3,987) Deferred revenue 13,202 (2,349) Deferred revenue 13,202 (2,349) Purchase of investments classified as available-for-sale 89,590 12,932 Muturities of investments classified as available-for-sale 69,597 10,887 Sales of investments classified as available-for-sale 65,787 10,887	Adjustments to reconcile net income to net cash provided by operating activities:		
Excess tax benefit from stock-based compensation (2,009) (5,423) Imputed interest on deferred payment obligations — 9.3 (Gain) loss on sale of patent assets (1,906) 5.88 Other (1,906) 5.88 Other (1,906) 5.88 Other (1,906) 5.88 Other 13 (11) Changes in assets and liabilities: 216 2,617 Other receivable 33,775 — Other receivables 33,378 — Prepatic expenses and other assets (3,348) 3,745 Accounts payable 13 (226) Accused and other liabilities 11,911 (3,987) Deferred revenue 13,202 (2,349) Net cash provided by operating activities 123,379 62,562 East flows from investing activities (98,505) 107,932 Maturities of investments classified as available-for-sale (55,78) 105,887 Sales of investments classified as available-for-sale (55,20) (45,765) Business acquis	Depreciation and amortization	47,	798 38,938
Imputed interest on deferred payment obligations — 93 (Gain) loss on sale of patent asserts 126 (177 Amortization of premium on investments 2,995 2,473 Deferred taxes (1,900) 588 Other 13 (11) Changes in assets and liabilities: 33,775 — Prepaid expenses and other assets 3,348 3,745 Accounts receivables 33,775 — Prepaid expenses and other assets 3,348 3,745 Accounts payable 13 (256 Accrued and other liabilities 1,191 3,987 Deferred revenue 13,202 (2,349) Deferred revenue 13,202 (2,349) Net cash provided by operating activities 123,379 6,252 Tuchases of investments classified as available-for-sale 9,8950 10,7932 Muturities of investments classified as available-for-sale 65,87 105,887 Sales of investments classified as available-for-sale 65,87 105,887 Business acquisition — 62,20 </td <td>Stock-based compensation</td> <td>8,</td> <td>186 5,012</td>	Stock-based compensation	8,	186 5,012
(Gain) loss on sale of patent assets 126 (177) Amortization of premium on investments 2,995 2,473 Deferred taxes (1,906) 588 Other 13 (111) Changes in assets and liabilities:	Excess tax benefit from stock-based compensation	(2,	009) (5,423)
Amortization of premium on investments 2,995 2,473 Deferred taxes (1,906) 588 Other 13 (11) Changes in assets and liabilities: Temperature receivable 216 2,617 Other receivables 33,775 — Prepaid expenses and other assets (3,348) 3,745 Accounts payable 130 (226) Accrued and other liabilities (1,191) (3,987) Deferred revenue 13,202 (2,349) Net cash provided by operating activities 13,302 (2,349) Purchases of investments classified as available-for-sale (98,950) (127,932) Maturities of investments classified as available-for-sale 65,787 105,887 Sales of investments classified as available-for-sale (98,950) (127,932) Maturities of investments classified as available-for-sale (65,787) 105,887 Sales of investments classified as available-for-sale (65,787) 105,887 Purchases of intrasticitied assetis (66,578) (65,765) Decrease in restricted cash (70,00)	Imputed interest on deferred payment obligations		— 93
Deferred taxes (1,906) 588 Other 13 (11) Changes in assets and liabilities: 1 (2,617) Accounts receivable 216 2,617 Other receivables 33,775 — Prepaid expenses and other assets (3,348) 3,745 Accounts payable 13,00 (2,639) Accured and other liabilities (1,191) (3,987) Deferred revenue 13,202 (2,349) Net cash provided by operating activities 123,379 62,562 Cash 1,093 7,232 Muturities of investments classified as available-for-sale 98,950 102,7932 Muturities of investments classified as available-for-sale 98,950 102,7932 Sales of investments classified as available-for-sale 98,950 102,7932 Muturities of investments classified as available-for-sale 65,787 105,887 Sales of investments classified as available-for-sale 65,787 105,887 Putchases of investments classified as available-for-sale 67 67 Putchases of investments classif	(Gain) loss on sale of patent assets		126 (177)
Other 13 (11) Changes in assets and liabilities: Capage	Amortization of premium on investments	2,9	995 2,473
Changes in assets and liabilities: 216 2,617 Accounts receivable 33,775 — Other receivables 33,348 3,745 Prepaid expenses and other assets 3,348 3,725 Accounts payable 130 (226) Accrued and other liabilities (1,191) 3,987 Deferred revenue 13,202 2,349 Net cash provided by operating activities 132,379 62,562 Cash flows from investing activities (98,950) (127,932) Maurities of investments classified as available-for-sale (98,950) (127,932) Maurities of investments classified as available-for-sale 10,999 — Sales of investments classified as available-for-sale 10,999 — Business acquisition — (45,765) Bucerease in restricted cash — (52 Purchases of property and equipment (874) (1,040) Acquisitions of patent assets (69,637) (36,730) Proceeds from sale of patent assets (100 200 Acta flows from financing activities <	Deferred taxes	(1,5	906) 588
Accounts receivables 33,775 — Other receivables 33,775 — Prepaid expenses and other assets (3,348) 3,745 Accounts payable 130 (226) Accrued and other liabilities (1,191) (3,987) Deferred revenue 13,202 (2,349) Net cash provided by operating activities 123,379 62,562 Cash flows from investing activities 89,950 (127,932) Maturities of investments classified as available-for-sale 65,787 105,887 Sales of investments classified as available-for-sale 65,87 105,887 Sales of investments classified as available-for-sale 1,099 — Business acquisition — (45,765) Decrease in restricted cash — 67 Purchases of intestments classified as available-for-sale — 67 Purchases of intestricted cash — 67 Purchases of property and equipment (67,007) (52) Purchases of patent assets (69,637) (36,730) Proceeds from sale of patent assets	Other		13 (11)
Other receivables 33,775 — Prepaid expenses and other assets (3,348) 3,745 Accounts payable 130 (226) Accrued and other liabilities (1,191) (3,987) Deferred revenue 13,202 (2,349) Net cash provided by operating activities 123,379 62,562 Cash flows from investing activities 89,950 (127,932) Maturities of investments classified as available-for-sale 68,950 (127,932) Maturities of investments classified as available-for-sale 55,787 105,887 Sales of investments classified as available-for-sale 1,099 — Business acquisition — (45,765) Decrease in restricted cash — (45,765) Decrease in restricted cash — 62 Purchases of intangible assets — 62 Purchases of property and equipment (87,40) (1,400) Acquisitions of patent assets (69,637) (36,730) Proceeds from sale of patent assets 100 200 Net cash used in investing activities	Changes in assets and liabilities:		
Prepaid expenses and other assets 3,348 3,745 Accounts payable 130 (226) Accrued and other liabilities (1,191) (3,987) Deferred revenue 13,202 (2,349) Net cash provided by operating activities 123,379 62,562 Cash flows from investing activities 9(89,50) (127,932) Muturities of investments classified as available-for-sale (98,950) (127,932) Adarwities of investments classified as available-for-sale 65,787 105,887 Sales of investments classified as available-for-sale 1,099 Business acquisition (45,765) Decrease in restricted cash 62 Purchases of intangible assets (52 Purchases of property and equipment (874) (1,400) Acquisitions of patent assets (69,637) (36,730) Proceeds from sale of patent assets (69,637) (36,730) Proceeds from functing activities (102,475) (105,145) Est Allows from financing activities (4,050)	Accounts receivable	:	2,617
Accounts payable 130 (26) Accrued and other liabilities (1,191) (3,987) Deferred revenue 13,202 (2,349) Net cash provided by operating activities 123,799 62,562 Cash flows from investing activities Purchases of investments classified as available-for-sale (98,950) (127,932) Maturities of investments classified as available-for-sale 65,787 105,887 Sales of investments classified as available-for-sale 1,099 Business acquisition (45,765) Decrease in restricted cash 67 Purchases of intengible assets 62 Purchases of property and equipment (874) (1,400) Acquisitions of patent assets (69,637) (36,730) Proceeds from sale of patent assets (69,637) (36,730) Proceeds from financing activities (4,050) Approach typic participal on deferred payment obligations (4,050) Proceeds from exercise of stock options and other common stock issuances 2,727 2,520	Other receivables	33,	775 —
Accrued and other liabilities (1,191) (3,987) Deferred revenue 13,202 (2,349) Net cash provided by operating activities 123,379 62,562 Cash flows from investing activities 89,505 (127,932) Purchases of investments classified as available-for-sale (98,950) (127,932) Maturities of investments classified as available-for-sale 1,099 - Sales of investments classified as available-for-sale 1,099 - Business acquisition - (45,765) Decrease in restricted cash - 647 Purchases of intangible assets - 622 Purchases of property and equipment (874) (1,400) Acquisitions of patent assets (69,637) (36,730) Proceeds from sale of patent assets 100 200 Net cash used in investing activities - (4,050) Repayments of principal on deferred payment obligations - (4,050) Proceeds from exercise of stock options and other common stock issuances 2,727 2,520 Excess tax benefit from stock-based compensation <t< td=""><td>Prepaid expenses and other assets</td><td>(3,</td><td>348) 3,745</td></t<>	Prepaid expenses and other assets	(3,	348) 3,745
Deferred revenue 13,202 (2,349) Net cash provided by operating activities 123,379 62,562 Cash flows from investing activities *** *** Purchases of investments classified as available-for-sale (98,950) (127,932) Maturities of investments classified as available-for-sale 65,787 105,887 Sales of investments classified as available-for-sale 1,099 - Business acquisition - (45,765) Decrease in restricted cash - 647 Purchases of intangible assets - 62 Purchases of property and equipment (874) (1,400) Acquisitions of patent assets (69,637) (36,730) Proceeds from sale of patent assets 100 200 Net cash used in investing activities (102,475) (105,105) Cash flows from financing activities - (4,050) Proceeds from exercise of stock options and other common stock issuances 2,727 2,520 Excess tax benefit from stock-based compensation 2,009 5,423 Net cash provided by financing activities 4,	Accounts payable		130 (226)
Net cash provided by operating activities 123,379 62,562 Cash flows from investing activities Use of provided by operating activities 109,950 (127,932) Purchases of investments classified as available-for-sale 65,787 105,887 Sales of investments classified as available-for-sale 1,099 — Business acquisition — (45,765) Decrease in restricted cash — 647 Purchases of intangible assets — (52) Purchases of property and equipment (69,637) (36,730) Acquisitions of patent assets (69,637) (36,730) Proceeds from sale of patent assets 100 200 Net cash used in investing activities (102,475) (105,145) Cash flows from financing activities — (4,050) Proceeds from exercise of stock options and other common stock issuances 2,727 2,520 Excess tax benefit from stock-based compensation 2,009 5,423 Net cash provided by financing activities 4,736 3,893 Net increase (decrease) in cash and cash equivalents 25,640 (38,690) </td <td>Accrued and other liabilities</td> <td>(1,</td> <td>191) (3,987)</td>	Accrued and other liabilities	(1,	191) (3,987)
Cash flows from investing activities Purchases of investments classified as available-for-sale (98,950) (127,932) Maturities of investments classified as available-for-sale 65,787 105,887 Sales of investments classified as available-for-sale 1,099 — Business acquisition — (45,765) Decrease in restricted cash — 647 Purchases of intangible assets — (52) Purchases of property and equipment (874) (1,400) Acquisitions of patent assets (69,637) (36,730) Proceeds from sale of patent assets 100 200 Net cash used in investing activities (102,475) (105,145) Cash flows from financing activities — (4,050) Proceeds from exercise of stock options and other common stock issuances 2,727 2,520 Excess tax benefit from stock-based compensation 2,009 5,423 Net cash provided by financing activities 4,736 3,893 Net increase (decrease) in cash and cash equivalents 25,640 (38,690) Cash and cash equivalents at be	Deferred revenue	13,:	202 (2,349)
Purchases of investments classified as available-for-sale (98,950) (127,932) Maturities of investments classified as available-for-sale 65,787 105,887 Sales of investments classified as available-for-sale 1,099 — Business acquisition — (45,765) Decrease in restricted cash — 627 Purchases of intangible assets — (52) Purchases of property and equipment (874) (1,400) Acquisitions of patent assets (69,637) (36,730) Proceeds from sale of patent assets 100 200 Net cash used in investing activities (102,475) (105,145) Cash flows from financing activities — (4,050) Proceeds from exercise of stock options and other common stock issuances 2,727 2,520 Excess tax benefit from stock-based compensation 2,009 5,423 Net cash provided by financing activities 4,736 3,893 Net increase (decrease) in cash and cash equivalents 25,640 (38,690) Cash and cash equivalents at beginning of period 73,638 106,749	Net cash provided by operating activities	123,	379 62,562
Maturities of investments classified as available-for-sale 65,787 105,887 Sales of investments classified as available-for-sale 1,099 — Business acquisition — (45,765) Decrease in restricted cash — 647 Purchases of intangible assets — (52) Purchases of property and equipment (874) (1,400) Acquisitions of patent assets (69,637) (36,730) Proceeds from sale of patent assets (102,475) (105,145) Cash flows from financing activities — (4,050) Repayments of principal on deferred payment obligations — (4,050) Proceeds from exercise of stock options and other common stock issuances 2,727 2,520 Excess tax benefit from stock-based compensation 2,009 5,423 Net cash provided by financing activities 4,736 3,893 Net increase (decrease) in cash and cash equivalents 25,640 (38,690) Cash and cash equivalents at beginning of period 73,638 106,749	Cash flows from investing activities		
Sales of investments classified as available-for-sale 1,099 — Business acquisition — (45,765) Decrease in restricted cash — 647 Purchases of intangible assets — (52) Purchases of property and equipment (874) (1,400) Acquisitions of patent assets (69,637) (36,730) Proceeds from sale of patent assets 100 200 Net cash used in investing activities (102,475) (105,145) Cash flows from financing activities — (4,050) Proceeds from exercise of stock options and other common stock issuances 2,727 2,520 Excess tax benefit from stock-based compensation 2,009 5,423 Net cash provided by financing activities 4,736 3,893 Net increase (decrease) in cash and cash equivalents 25,640 (38,690) Cash and cash equivalents at beginning of period 73,638 106,749	Purchases of investments classified as available-for-sale	(98,	950) (127,932)
Business acquisition — (45,765) Decrease in restricted cash — 647 Purchases of intangible assets — (52) Purchases of property and equipment (874) (1,400) Acquisitions of patent assets (69,637) (36,730) Proceeds from sale of patent assets 100 200 Net cash used in investing activities (102,475) (105,145) Cash flows from financing activities — (4,050) Proceeds from exercise of stock options and other common stock issuances 2,727 2,520 Excess tax benefit from stock-based compensation 2,009 5,423 Net cash provided by financing activities 4,736 3,893 Net increase (decrease) in cash and cash equivalents 25,640 (38,690) Cash and cash equivalents at beginning of period 73,638 106,749	Maturities of investments classified as available-for-sale	65,	787 105,887
Decrease in restricted cash — 647 Purchases of intangible assets — (52) Purchases of property and equipment (874) (1,400) Acquisitions of patent assets (69,637) (36,730) Proceeds from sale of patent assets 100 200 Net cash used in investing activities (102,475) (105,145) Cash flows from financing activities — (4,050) Proceeds from exercise of stock options and other common stock issuances 2,727 2,520 Excess tax benefit from stock-based compensation 2,009 5,423 Net cash provided by financing activities 4,736 3,893 Net increase (decrease) in cash and cash equivalents 25,640 (38,690) Cash and cash equivalents at beginning of period 73,638 106,749	Sales of investments classified as available-for-sale	1,	099 —
Purchases of intangible assets — (52) Purchases of property and equipment (874) (1,400) Acquisitions of patent assets (69,637) (36,730) Proceeds from sale of patent assets 100 200 Net cash used in investing activities (102,475) (105,145) Cash flows from financing activities — (4,050) Proceeds from exercise of stock options and other common stock issuances 2,727 2,520 Excess tax benefit from stock-based compensation 2,009 5,423 Net cash provided by financing activities 4,736 3,893 Net increase (decrease) in cash and cash equivalents 25,640 (38,690) Cash and cash equivalents at beginning of period 73,638 106,749	Business acquisition		— (45,765)
Purchases of property and equipment (874) (1,400) Acquisitions of patent assets (69,637) (36,730) Proceeds from sale of patent assets 100 200 Net cash used in investing activities (102,475) (105,145) Cash flows from financing activities — (4,050) Repayments of principal on deferred payment obligations — (4,050) Proceeds from exercise of stock options and other common stock issuances 2,727 2,520 Excess tax benefit from stock-based compensation 2,009 5,423 Net cash provided by financing activities 4,736 3,893 Net increase (decrease) in cash and cash equivalents 25,640 (38,690) Cash and cash equivalents at beginning of period 73,638 106,749	Decrease in restricted cash		— 647
Acquisitions of patent assets(69,637)(36,730)Proceeds from sale of patent assets100200Net cash used in investing activities(102,475)(105,145)Cash flows from financing activitiesRepayments of principal on deferred payment obligations—(4,050)Proceeds from exercise of stock options and other common stock issuances2,7272,520Excess tax benefit from stock-based compensation2,0095,423Net cash provided by financing activities4,7363,893Net increase (decrease) in cash and cash equivalents25,640(38,690)Cash and cash equivalents at beginning of period73,638106,749	Purchases of intangible assets		— (52)
Proceeds from sale of patent assets100200Net cash used in investing activities(102,475)(105,145)Cash flows from financing activitiesRepayments of principal on deferred payment obligations—(4,050)Proceeds from exercise of stock options and other common stock issuances2,7272,520Excess tax benefit from stock-based compensation2,0095,423Net cash provided by financing activities4,7363,893Net increase (decrease) in cash and cash equivalents25,640(38,690)Cash and cash equivalents at beginning of period73,638106,749	Purchases of property and equipment	(1)	874) (1,400)
Net cash used in investing activities(102,475)(105,145)Cash flows from financing activitiesUse of principal on deferred payment obligations—(4,050)Proceeds from exercise of stock options and other common stock issuances2,7272,520Excess tax benefit from stock-based compensation2,0095,423Net cash provided by financing activities4,7363,893Net increase (decrease) in cash and cash equivalents25,640(38,690)Cash and cash equivalents at beginning of period73,638106,749	Acquisitions of patent assets	(69,	637) (36,730)
Cash flows from financing activitiesRepayments of principal on deferred payment obligations—(4,050)Proceeds from exercise of stock options and other common stock issuances2,7272,520Excess tax benefit from stock-based compensation2,0095,423Net cash provided by financing activities4,7363,893Net increase (decrease) in cash and cash equivalents25,640(38,690)Cash and cash equivalents at beginning of period73,638106,749	Proceeds from sale of patent assets		100 200
Repayments of principal on deferred payment obligations—(4,050)Proceeds from exercise of stock options and other common stock issuances2,7272,520Excess tax benefit from stock-based compensation2,0095,423Net cash provided by financing activities4,7363,893Net increase (decrease) in cash and cash equivalents25,640(38,690)Cash and cash equivalents at beginning of period73,638106,749	Net cash used in investing activities	(102,	475) (105,145)
Proceeds from exercise of stock options and other common stock issuances2,7272,520Excess tax benefit from stock-based compensation2,0095,423Net cash provided by financing activities4,7363,893Net increase (decrease) in cash and cash equivalents25,640(38,690)Cash and cash equivalents at beginning of period73,638106,749	Cash flows from financing activities		
Proceeds from exercise of stock options and other common stock issuances2,7272,520Excess tax benefit from stock-based compensation2,0095,423Net cash provided by financing activities4,7363,893Net increase (decrease) in cash and cash equivalents25,640(38,690)Cash and cash equivalents at beginning of period73,638106,749	Repayments of principal on deferred payment obligations		— (4,050)
Excess tax benefit from stock-based compensation2,0095,423Net cash provided by financing activities4,7363,893Net increase (decrease) in cash and cash equivalents25,640(38,690)Cash and cash equivalents at beginning of period73,638106,749		2,	
Net cash provided by financing activities4,7363,893Net increase (decrease) in cash and cash equivalents25,640(38,690)Cash and cash equivalents at beginning of period73,638106,749	•		
Net increase (decrease) in cash and cash equivalents25,640(38,690)Cash and cash equivalents at beginning of period73,638106,749	· · · · · · · · · · · · · · · · · · ·		
Cash and cash equivalents at beginning of period 73,638 106,749			
	Cash and cash equivalents at end of period	· · · · · · · · · · · · · · · · · · ·	_

Reconciliation of Pro Forma Net Income Per Share

(in thousands, except per share data)

(unaudited)

	Three Months Ended			Six Months Ended					
	June 30,				June 30,				
	 2013 2012		2013			2012			
Net income	\$ 10,697	\$	13,188	\$	25,392	\$	21,269		
Pro forma net income per share:									
Basic	\$ 0.21	\$	0.26	\$	0.49	\$	0.43		
Diluted	\$ 0.20	\$	0.25	\$	0.48	\$	0.40		
Shares used in computing pro forma net income per share:									
Basic:									
Basic weighted-average common shares	51,774		49,454		51,489		48,881		
Add: Restricted stock	31		809		45		1,146		
Shares used in computing pro forma basic net income per share	 51,805		50,263		51,534		50,027		
Diluted:									
Diluted weighted-average common shares	53,463		51,787		53,055		51,517		
Add: Restricted stock	31		809		45		1,146		
Shares used in computing pro forma diluted net income per share	53,494		52,596		53,100		52,663		

RPX Corporation

Reconciliation of GAAP to Pro Forma Non-GAAP Net Income Per Share (in thousands, except per share data)

		Three Months Ended				Six Months Ended				
		Jun	e 30,		June 30,					
		2013 2012		2012 2013		2013		2012		
Net income	\$	10,697	\$	13,188	\$	25,392	\$	21,269		
Stock-based compensation ^[1]		4,658		2,608		8,436		5,281		
Amortization of acquired intangible assets ^[2]		358		321		718		471		
Income tax adjustments ^[3]		(1,676)		(747)		(2,961)		(1,635)		
Non-GAAP net income	\$	14,037	\$	15,370	\$	31,585	\$	25,386		
Pro forma non-GAAP net income per share:	_									
Basic	\$	0.27	\$	0.31	\$	0.61	\$	0.51		
Diluted	\$	0.26	\$	0.29	\$	0.59	\$	0.48		
Pro forma weighted-average shares:										
Basic		51,805		50,263		51,534		50,027		
Diluted		53,494		52,596		53,100		52,663		
			_		_					

RPX Corporation Reconciliation of GAAP to Non-GAAP Cost of Revenue (in thousands)

(unaudited)

	Three Months Ended					Six Months Ended				
	June 30,				June 30,					
	 2013	2012			2013	2012				
Cost of revenue	\$ 24,694	\$	20,511	\$	48,364	\$	38,528			
Amortization of acquired intangible assets ^[2]	(56)		(56)		(112)		(112)			
Non-GAAP cost of revenue	\$ 24,638	\$	20,455	\$	48,252	\$	38,416			

RPX Corporation Reconciliation of GAAP to Non-GAAP Selling, General and Administrative Expenses (in thousands)

	Three Months Ended				Six Months Ended					
	June 30,					June 30,				
	2013			2012		2013		2012		
Selling, general and administrative expenses	\$	15,736	\$	13,533	\$	30,209	\$	26,756		
Stock-based compensation ^[1]		(4,658)		(2,608)		(8,436)		(5,281)		
Amortization of acquired intangible assets ^[2]		(302)		(265)		(606)		(359)		
Non-GAAP selling, general and administrative expenses	\$	10,776	\$	10,660	\$	21,167	\$	21,116		

RPX Corporation Additional Metrics

(in thousands, except client and headcount data)

(unaudited)

As of and for the Three Months Ended June 30, **Operating Metrics** 2013 2012 Number of clients 157 120 Net additions 11 4 Trailing four quarters 37 24 Gross acquisition spend \$ 41,100 \$ 107,684 \$ Trailing four quarters 201,273 \$ 183,709 Net acquisition spend \$ 39,100 \$ 53,454 \$ 118,073 Trailing four quarters \$ 124,854 Full time equivalent headcount 123 126 As of and for the Three Months Ended June 30, **Financial Metrics** 2013 2012 \$ \$ Subscription revenue^[4] 54,979 45,813 Fee-related revenue 2,502 9,425 \$ 57,481 \$ 55,238 Revenue Cash, cash equivalents and short-term investments \$ 259,305 \$ 219,876

Deferred revenue, current and noncurrent

\$

117,573

\$

105,980

^[1] RPX excludes stock-based compensation and related employer payroll taxes from its non-GAAP financial measures.

PRPX excludes amortization expense related to intangible assets (other than patents) acquired in conjunction with the acquisition of businesses from its non-GAAP financial measures.

[3] Amount reflects income taxes associated with the above noted non-GAAP exclusions.

^[4] Subscription revenue is comprised of revenue generated from membership subscription services and premiums earned from insurance policies.